Skip to main content

Table 1 Baseline characteristics and risk factors in patients with angiographically proven CAD, and previous MI as compared to controls without CAD.

From: Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)

   Controls CAD p CAD and MI p
  Male (n = 360) (n = 1891)   (n = 1060)  
  Female (n = 333) (n = 635)   (n = 279)  
Age (years) means ± SD Male 55 ± 12 63 ± 10   63 ± 10  
  Female 62 ± 10 66 ± 10 <0.0011 65 ± 10 <0.0011
Body mass index (kg/m2) means ± SD Male 27 ± 4 28 ± 4   27 ± 4  
  Female 27 ± 5 27 ± 5 n.s.2 27 ± 5 n.s.2
Smoker (former and current) Male 239 (66%) 1487 (78%)   867 (82%)  
  Female 100 (30%) 253 (39%) <0.0014 145 (51%) <0.0014
Diabetes mellitus Male 63 (17%) 653 (34%)   374 (35%)  
  Female 66 (20%) 253 (39%) <0.0014 120 (42%) <0.0014
Systemic Hypertension Male 212 (58%) 1399 (74%)   736 (69%)  
  Female 228 (69%) 519 (81%) 0.0024 220(77%) n.s.4
Fasting blood glucose (mmol/L) means ± SD Male 5,89 ± 1,67 6,39 ± 1,89   6,34 ± 1,83  
  Female 5,78 ± 1,34 6,6 ± 2,44 <0.0012 6,67 ± 2,5 <0.0012
LDL-C(mmol/L) means ± SD Male 3,02 ± 0,8 2,92 ± 0,85   2,84 ± 0,83  
  Female 3,2 ± 0,8 3,2 ± 1,01 0.0023 3,05 ± 1,01 n.s.3
HDL-C (mmol/L) means ± SD Male 1,03 ± 0,28 0,93 ± 0,23   0,9 ± 0,23  
  Female 1,19 ± 0,31 1,09 ± 0,28 <0.0013 1,03 ± 0,28 <0.0013
Bilirubin (μmol/L) means ± SD Male 13,17 ± 7,53 11,46 ± 6,33   10.95 ± 5.82  
  Female 9.58 ± 4,62 8,89 ± 6,16 <0.0012 8,38 ± 4,10 <0.0012
Iron (μmol/L) Male 19,52 ± 8.06 16,66 ± 6,98   16,12 ± 6,98  
  Female 17,19 ± 6,09 14,69 ± 5,91 <0.0012 13,97 ± 5,91 <0.0012
Triglycerides (mmol/L)
median (25th and 75th percentile)
Male 1,64
(1,16–2,4)
1,69
(1,26–2,27)
  1,7
(1,26–2,25)
 
  Female 1,44
(1,04–2,01)
1,73
(1,3–2,34)
<0.0123 1,75
(1,31–2,46)
n.s.3
  1. 1analysis of variance adjusted for gender only
  2. 2analysis of variance adjusted for age and gender
  3. 3analysis of variance additionally adjusted for use of lipid-lowering drugs
  4. 4logistic regression, adjusted for age and gender